Ptc Therapeutics (PTCT) Return on Capital Employed (2013 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Return on Capital Employed of 5.49% for Q2 2026, down 3013.0% year-over-year from 0.19% in Q2 2025, and up 284.43% quarter-over-quarter from 2.98% in Q1 2026.
Ptc Therapeutics (PTCT) Return on Capital Employed (2013 - 2026) Analysis & Trends
Ptc Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 5.49% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 3013.0% year-over-year to 5.49%; the TTM figure through Jun 2026 stood at 5.49% (down 3013.0% YoY), while the FY2025 annual figure was 65.01%, up 8983.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 5.49%, up from 2.98% in the prior quarter.
- The five-year high for Return on Capital Employed was 48.09% in Q4 2025, with the low at 80.02% in Q3 2023.
- The 5-year median for Return on Capital Employed is 25.72% (2024), against an average of 13.74%.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed sank 5390 bps in 2023, then soared 7396 bps in 2025.
- Ptc Therapeutics' Return on Capital Employed stood at 36.23% in 2022, then decreased by 24 bps to 45.09% in 2023, then surged by 44 bps to 25.37% in 2024, then surged by 290 bps to 48.09% in 2025, then tumbled by 89 bps to 5.49% in 2026.
- Business Quant data shows PTCT's Return on Capital Employed at 5.49% in Q2 2026, 2.98% in Q1 2026, and 48.09% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 5.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.49% |
| Mar 31, 2026 | -2.98% |
| Dec 31, 2025 | 48.09% |
| Sep 30, 2025 | 43.77% |
| Jun 30, 2025 | 35.62% |
| Mar 31, 2025 | 45.00% |
| Dec 31, 2024 | -25.37% |
| Sep 30, 2024 | -10.59% |
| Jun 30, 2024 | -15.93% |
| Mar 31, 2024 | -28.97% |
| Dec 31, 2023 | -45.09% |
| Sep 30, 2023 | -80.02% |
| Jun 30, 2023 | -59.74% |
| Mar 31, 2023 | -39.36% |
| Dec 31, 2022 | -36.23% |
| Sep 30, 2022 | -26.12% |
| Jun 30, 2022 | -28.89% |
| Mar 31, 2022 | -26.06% |
| Dec 31, 2021 | -25.59% |
| Sep 30, 2021 | -24.63% |